This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

migalastat (Galafold®)

Reference No. 2003

Publication date:

Appraisal information

migalastat (Galafold®) 123 mg capsule

Company: Amicus Therapeutics Inc
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: 15/02/2017
Submission Type: NICE HST
Status: Recommended
Advice No: Not available
Ratification by Welsh Government: 13/03/2017

Current Progress

Ratification by
Welsh Government

AWMSG advice

The National Institute for Health and Care Excellence (NICE) published advice in February 2017 in relation to migalastat (Galafold®) for the long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation. At their meeting on 15th February 2017, AWMSG supported the adoption and implementation of this advice within NHS Wales (refer to the minutes of meetings). Welsh Government has subsequently agreed that the NICE HST advice for migalastat (Galafold®) should be implemented within NHS Wales. Refer to the NICE website for full guidance including any specific restrictions on the use of the technology.